Placebo Controlled Study of Sublingual Salvinorin A — 6A  

Pharmaceutical Preparations Clinical Trial

Official title: A Double Blind Placebo Controlled Ascending Dose Pharmacodynamic and Tolerability Study of 100 to 4000 µg of Sublingual Salvinorin A

Status Completed

Clinical Trial Summary

In this study, our aim is to determine an active but tolerable sublingual dose (range 100 to 4000 µg) of Salvinorin A (SA) in experienced subjects. This study is an ascending-dose, placebo-controlled, single-site design in 8 Salvia-experienced subjects. Subjects will receive SA doses from 0-4000 µg. Doses will be separated by at least one day. The first two doses (0 and 100µg) will be double-blinded while the last four (250, 500, 1000, 2000 and 4000µg) will be single-blind.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)

Related Conditions & MeSH terms

• Pharmaceutical Preparations

• NCT number: NCT01149824
• Study type: Interventional
• Source: California Pacific Medical Center Research Institute
• Status: Completed
• Phase: N/A
• Start date: June 2009
• Completion date: October 2010